Johnson & Johnson Services, Inc., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.,) are Dominating the North America Alopecia Treatment (Hair Loss) Market in 2019

North America Alopecia Treatment (Hair Loss) Market is expected to grow with the CAGR of 5.4% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/north-america-alopecia-treatment-hair-loss-market

North America alopecia treatment (hair loss) market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in global alopecia treatment (hair loss) market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In March 2018, Johnson & Johnson Services, Inc teamed up with JW Pharmaceutical. The company has taken this decision in order to enhance the sales of Rogaine, a hair loss treatment containing minoxidil. Rogaine is a FDA approved alopecia treatment and is one of the top selling hair loss treatment brands. This initiative helped the company to enhance the company’s overall revenue.

Johnson & Johnson Services, Inc., is the dominating player in alopecia treatment (hair loss) market. The other key players existing in the market are iGrow Laser, Lexington Intl., LLC., Curallux, LLC., HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, WOCKHARDT, Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceuticals Industries Ltd.), Pfizer Inc., Par Pharmaceutical (A Subsidiary of Endo International plc),  GlaxoSmithKline plc,  Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc. (A subsidiary of Zydus Cadila), Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc., Aurobindo Pharma,  Perrigo Company plc, Viviscal Limited (A Subsidiary of Church & Dwight Co.), Dr. Kurt Wolff GmbH & Co. KG,  Labo International S.r.l. ,  Watermans, WON TECH Co., Ltd. , PureTech, among others.

North America Alopecia Treatment (Hair Loss) MarketJohnson & Johnson Services, Inc

Johnson & Johnson Services, Inc headquarter is in New Jersey, U.S. The company was founded in the year 1886. The company is focused on improving access and affordability, create healthier communities and put a healthy mind, body and environment within reach of everyone, everywhere. The company has three business segments including Consumer, Pharmaceutical, Medical Devices in these Consumer is the market focused segment. The company has wide product categories such as Consumer Health Products, Medical Devices, Pharmaceutical Products in which Consumer Health Products is the market focused category.

For instance,

  • In September 2017, Johnson & Johnson Services, Inc presented new scientific data at European Academy of Dermatology and Venerology (EADV) Annual Meeting held in Geneva, Switzerland. During this meeting the company presented new finding in field of skin microbiome, and treatment of androgenetic alopecia (hair loss) among others. The company also mentioned about its scientists which are continuously developing transformative solutions involving alopecia treatment (hair loss) among others. The company has also highlighted the data demonstrating the mechanism of action of minoxidil foam (Regaine). This initiative taken by the company created awareness among people regarding the hair loss treatment tat the company is manufacturing.

The company has wide presence across Asia, Europe, America, Middle East & Africa. The company also has various subsidiary companies such as Janssen Pharmaceutica (Belgium), Neutrogena (U.S.), DePuy Synthes Companies (U.S), Ethicon Inc. (U.S.), ALZA Corporation (U.S.) among others.

 GlaxoSmithKline plc

 GlaxoSmithKline plc founded in the year 1715, headquartered in Ontario, Canada. The company is focused on bringing differentiated, high quality and needed healthcare products to as many people as possible with its three global businesses, scientific and technical know- how and talented people. The company operates its business through three business segments which are Pharmaceuticals, Vaccines, Consumer Healthcare in which Pharmaceuticals is the market focused segment. The company has wide product categories which are Our Prescription Medicines, Our Vaccines, Our Consumer Healthcare Products, ViV Healthcare, Stiefel- Dermatology in which Our Prescription Medicines is the market focused categories.

  • In August 2019, GlaxoSmithKline plc obtained positive views from Koreans regarding the usage of Avodart as a hair loss treatment. Avodart works by blocking the dihydrotestosterone (DHT) which is responsible for baldness highly observed among men. This positive outcome helped the company to attain a lucrative growth in sales of alopecia treatment which has boosted the company’s overall revenue.

The company has presence across Africa, Asia & Middle East, Australasia, Europe, North America, South and Central America. The company has various subsidiaries such 1506369 Alberta ULC( Canada), Action Potential Venture Capital Limited(England), Adechsa GmbH (Switzerland), Alenfarma – Especialidades Farmaceuticas, Limitada (Portugal), Allen & Hanburys Pharmaceutical Nigeria Limited( Nigeria)  among others.

Merck Sharp & Dohme Corp. (A Subsidiary of Merck & Co., Inc.)

Merck Sharp & Dohme Corp. (A Subsidiary of Merck & Co., Inc.) incorporated in 1953, headquartered in New Jersey, U.S. The company is focused on innovation and scientific excellence in order to deliver medicines, vaccines and animal health products that can help millions around the world. The company operates its business through business segments which are Localized Therapies is the market focused segment. The company has product categories that are PROPECIA (finasteride) is the market focused category.

  • In October 2013, Merck Sharp & Dohme Corp. (A Subsidiary of Merck & Co., Inc.) announced the economic benefit is obtained by selling the Propecia among other products. The company has earned USD 68 million in 2013 from Propecia which is more than that of the sale of 2012 which is USD 67 million. Such benefits allowed the company to attain a lucrative growth in its overall revenue.

The company has presence in The Americas, Europe, Asia, Middle and South America.